These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17226105)

  • 1. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology".
    Rathmann W; Herder C
    Horm Metab Res; 2007 Jan; 39(1):1-2. PubMed ID: 17226105
    [No Abstract]   [Full Text] [Related]  

  • 2. Adiponectin--an adipokine with unique metabolic properties.
    Wiecek A; Adamczak M; Chudek J
    Nephrol Dial Transplant; 2007 Apr; 22(4):981-8. PubMed ID: 17234664
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of adiponectin in obesity, diabetes, and cardiovascular disease.
    Kawano J; Arora R
    J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure.
    Wannamethee SG; Whincup PH; Lennon L; Sattar N
    Arch Intern Med; 2007 Jul; 167(14):1510-7. PubMed ID: 17646605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease.
    von Eynatten M; Hamann A; Twardella D; Nawroth PP; Brenner H; Rothenbacher D
    Eur Heart J; 2008 May; 29(10):1307-15. PubMed ID: 18390868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular risk factors in hemodialysis patients--reverse epidemiology].
    Cordtz J; Ladefoged SD
    Ugeskr Laeger; 2007 Aug; 169(33):2609-13. PubMed ID: 17725905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
    Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
    J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?
    Rubin C; Nolin TD; Himmelfarb J
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):506-11. PubMed ID: 18089962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin and cardiovascular disease: response to therapeutic interventions.
    Han SH; Quon MJ; Kim JA; Koh KK
    J Am Coll Cardiol; 2007 Feb; 49(5):531-8. PubMed ID: 17276175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular actions of adiponectin: pathophysiologic implications.
    Maia-Fernandes T; Roncon-Albuquerque R; Leite-Moreira AF
    Rev Port Cardiol; 2008 Nov; 27(11):1431-49. PubMed ID: 19227810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age on 6-month survival in patients with cardiovascular risk factors undergoing elective non-cardiac surgery.
    Naughton C; Feneck RO
    Int J Clin Pract; 2007 May; 61(5):768-76. PubMed ID: 17493090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?
    de Zeeuw D; Bakker SJ
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S10-4. PubMed ID: 18580860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prognosis and risk factors of cardiovascular complications in patients with chronic glomerulonephritis].
    Mukasheva SB; Movchan EA
    Klin Med (Mosk); 2007; 85(2):36-9. PubMed ID: 17520887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further inflammatory information on metabolic syndrome by adiponectin evaluation.
    Matsushita K; Tamakoshi K; Yatsuya H; Wada K; Otsuka R; Takefuji S; Hotta Y; Kondo T; Murohara T; Toyoshima H
    Int J Cardiol; 2008 Mar; 124(3):339-44. PubMed ID: 17433469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced predictive power of quantitative TWA during routine exercise testing in the Finnish Cardiovascular Study.
    Minkkinen M; Kähönen M; Viik J; Nikus K; Lehtimäki T; Lehtinen R; Kööbi T; Turjanmaa V; Kaiser W; Verrier RL; Nieminen T
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):408-15. PubMed ID: 19175840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin: from obesity to cardiovascular disease.
    Antoniades C; Antonopoulos AS; Tousoulis D; Stefanadis C
    Obes Rev; 2009 May; 10(3):269-79. PubMed ID: 19389061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies.
    Shetty S; Kusminski CM; Scherer PE
    Trends Pharmacol Sci; 2009 May; 30(5):234-9. PubMed ID: 19359049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin and cardiovascular risk prediction: can the ambiguities be resolved?
    Wannamethee SG
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):581-4. PubMed ID: 18804989
    [No Abstract]   [Full Text] [Related]  

  • 19. [Strategies for cardiovascular diseases].
    Hjermann I
    Tidsskr Nor Laegeforen; 1992 Sep; 112(21):2738-9. PubMed ID: 1412302
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factor conundrum.
    Chait R
    Cardiology; 2010; 115(1):61-3. PubMed ID: 19864900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.